XORTX regains Nasdaq compliance after reverse stock split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
XORTX Meets Nasdaq Continued Listing Requirements
April 21, 2026 7:00 AM EDTCALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has received a letter of compliance from the Nasdaq Stock Market LLCs ("Nasdaq) Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires a listed companys shares to maintain a minimum bid price of US$1.00 per share (the Minimum Bid Requirement). In order to... More
